{"id":1380,"createDateTime":"2026-09-03T06:55:21.319Z","archiveDateTime":"2027-12-31T00:00:00.000Z","name":"Managing breakthrough bleeding without abandoning treatment ","image":"86c559e6ca3c3b44d34ba50452edd2a90f5953fce6ca56347f79379a","imageThumbnail":"16bc604ed546a3e390d3e9f395c996760b63dc803851227edb603c72","about":"This activity provides a practical approach to assessing expected versus concerning bleeding, modifying pill formulations, managing pharmacy substitution issues, and counselling patients to improve adherence and continuation. \n\nThis activity comprises a short educational video, followed by a reflective activity. Participants must complete both components to qualify for 30 minutes of Reviewing Performance (RP) Hours. \n\n# Learning Outcomes\n1. Outline how to assess a patient with breakthrough bleeding on hormonal contraception, including adherence, missed pills and formulation.\n2. Reflect on recent patient counselling to identify ways to reduce early discontinuation from breakthrough bleeding.\n3. Identify one strategy to improve communication with community pharmacists about contraceptive pill substitutions.\n\n# Provider\nThe Provider of this activity is [Praxhub](https://app.praxhub.com/orgs/1). Praxhub is an accredited Major Provider under the RACGP CPD Program. For any questions regarding this activity please contact support@praxhub.com. ","type":"video","summaryViewCount":127,"startDateTime":null,"durationSecs":409,"organisation":{"id":101,"name":"Arrotex","logoImage":"343d2282723763f021df947917df828894bcf90cd0942a7b794bdcd8","logoImageThumbnail":"4cb9c205c6d9ce99135b8445d977a6b5da5a4f07cbd1b9811fbd93f2","industry":"Pharmaceutical"},"provider":{"id":1,"name":"Praxhub","logoImage":"7d8c82e84cfeb7556fa842c1980c93b8144ab0959b0630c17e557baf","logoImageThumbnail":"78ba1e568155afb45aa67fc6f7337c076b0a1aa9182ceb80ac9b1095","industry":"Health Technology"},"commentCount":0,"likeCount":0,"presenters":[{"id":78297,"specialty":{"id":73,"name":"Obstetrics and Gynaecological Ultrasound"},"name":"A/Prof Gino Pecoraro","title":"Obstetrician and Gynaecologist","profileImage":"3cd8d5391f0edbcb8e4110c83b97297a905336799367ccdc8a034d35","profileImageThumbnail":"cb5f65a3a020d399e39d303674aa27c5f26524078b42d4e0b0e88452"}],"relatedEducation":[{"id":1361,"name":"Pelvic Pain and Endometriosis: Assessment and Management in Primary Care","image":"cb012a9add020bcb55ab8dce95d047c7bfbe6d64ad7abccf8a30aa51","imageThumbnail":"e8f1d298d1945e1e2dcc8aaa81ded371a3c05377583bbc9f81f06755","type":"zoom-webinar","startDateTime":"2026-09-15T09:30:00.000Z","durationSecs":5400,"associationEducationTypes":["EA","MO","RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1373,"name":"Hormonal Acne Management for General Practice","image":"8980d52fa2537eff660b08b44f79752a006b26b23d223206ddf22a8a","imageThumbnail":"bb0b3a191abc66b9631de005b87931e2765d514fc7d71ae5d2fd8f57","type":"zoom-webinar","startDateTime":"2026-10-08T08:30:00.000Z","durationSecs":5400,"associationEducationTypes":["EA","MO","RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1386,"name":"Oral Contraception: From Evidence to Practice","image":"42d0a4f8a46f82c540c4c00afded1b3fc29d0ff0c0c808504d3cc458","imageThumbnail":"4b3f571a5a638bcdc9c3d417204de62c4244bd5b7e63d21fe20d6a61","type":"video","startDateTime":null,"durationSecs":5339,"associationEducationTypes":["EA","MO","RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1381,"name":"Choosing the Right Pill for the Right Patient: COC or POP? ","image":"a182128e51e493ebc78e9de08e1a8a57c2c006fea237ec61df2fbc98","imageThumbnail":"53f699e434e8e398ffbdb6db29259fd5ba3e14fbb20a5c29cb127710","type":"video","startDateTime":null,"durationSecs":801,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1371,"name":"Fracture risk perception and medication adherence","image":"8a32746a58f9ae41f671a7e9c947bb28f50471654044468665d3c5e7","imageThumbnail":"0563278e7f8893527677202c291cc4fc492c520ca53ccc1b743c91e6","type":"video","startDateTime":null,"durationSecs":454,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}},{"id":1370,"name":"Pharmacological considerations for long-term antiresorptive drug (ARD) therapy ","image":"486aaf82a6cd773abd54f88e7e0df641b671075061b3281e755c87af","imageThumbnail":"bf7fe9ca785b08607ae90187607860a533437433ba322ada091c4858","type":"video","startDateTime":null,"durationSecs":677,"associationEducationTypes":["RP"],"organisation":{"id":101,"name":"Arrotex"}}]}